CagriSema and Amylin: What the Next Generation of Weight Loss Treatments Means for UK Patients

9 min read
Unbranded injection pen, clear vial and plain notebook in a soft-lit cream setting

 

CagriSema is a once-weekly injection combining cagrilintide, a long-acting amylin analogue, with semaglutide; in a major trial, it produced around 20% average weight loss over 68 weeks. It is not licensed or available in the UK today, and SwiftDoctor does not prescribe it.

Medically reviewed by Dr Saira Bano BMBS, BMedSci, MRCGP, PGCert MedEd, SCOPE-Certified Obesity Specialist
Reading time: 7 minutes · 16 November 2026

In this guide

  1. What is amylin and why does it matter for weight loss?
  2. What is CagriSema and what did the trials find?
  3. How does CagriSema compare with Mounjaro and Wegovy?
  4. Is CagriSema available in the UK?
  5. What else is coming in the amylin class?
  6. What does this mean for you now?
  7. When should you speak to a clinician?
  8. Frequently asked questions

There is growing interest in a different group of medicines being studied for weight management: amylin analogues. CagriSema is one of the most advanced candidates, combining an amylin analogue with semaglutide, a GLP-1 medicine.

The trial results are encouraging, but they do not tell us whether the medicine will be approved, when it might reach the UK, or whether it would suit an individual patient. Here is what the research shows so far, and what it means for treatment choices today.

What is amylin and why does it matter for weight loss?

Amylin is a hormone released alongside insulin by pancreatic beta cells. It helps signal fullness, slows stomach emptying and reduces the rise in glucagon that can follow a meal. [4]

Amylin is attracting interest because it may affect appetite and energy balance in ways that differ from GLP-1 medicines. Research suggests it can make the brain more responsive to leptin, another hormone involved in appetite regulation. It may also help counter some of the reduction in energy expenditure that normally happens during weight loss. These mechanisms are still being studied; they do not guarantee greater or more sustainable weight loss for an individual.

There are other research questions, too. Amylin is part of the calcitonin peptide family, which has led researchers to investigate possible effects on bone. Preclinical research has also raised questions about whether amylin receptors on muscle satellite cells could help preserve muscle. Neither bone protection nor muscle preservation is established as a clinical benefit in people taking amylin analogues.

Amylin-based treatment is not entirely new. Pramlintide was approved in the US in 2005 for people with diabetes who use insulin, but it requires multiple daily injections and was never authorised in the UK. Longer-acting medicines that can be given weekly have renewed interest in the field. [4, 5]

What is CagriSema and what did the trials find?

CagriSema is an investigational once-weekly injection combining cagrilintide 2.4 mg and semaglutide 2.4 mg. The two medicines are held in separate compartments in one pen. It is still a research medicine, not an approved treatment. [2, 3]

In REDEFINE 1, 3,417 adults with overweight or obesity, but without diabetes, were followed for 68 weeks. Average weight change was −20.4% with CagriSema compared with −3.0% with placebo. At least 5% weight loss was reached by 79.6% of participants receiving CagriSema and 39.9% receiving placebo. The combination also led to greater weight loss than either cagrilintide or semaglutide alone in the trial. [2, 3]

Among participants who started with obesity, around half were no longer classified as having obesity at week 68; 23% reached the normal-weight range. A body-composition substudy of 252 participants found that 67% of weight lost was fat mass and 33% was lean soft tissue. [3]

In REDEFINE 2, which enrolled 1,206 adults with overweight or obesity and type 2 diabetes, average weight change at 68 weeks was −13.7% with CagriSema and −3.4% with placebo. HbA1c, a measure of average blood glucose, fell by 1.8% versus 0.4%. More than 10% weight loss was reached by 66% versus 10%, and 35% versus 8% reduced the intensity of their glucose-lowering medicines. [3]

Digestive side effects were the most common, particularly during dose increases, and were mostly mild to moderate. Side effects led 6% of participants in REDEFINE 1 and 8% in REDEFINE 2 to stop treatment. [3]

Two abstract navy and coral forms meeting on a warm cream background

One finding may shape how future treatments are used: in REDEFINE 1, people who did not tolerate the highest dose lost about as much weight as those who did. There was no clear relationship between reaching the top dose and losing more weight. This supports further research into using the lowest effective dose, rather than assuming everyone should reach the maximum.

How does CagriSema compare with Mounjaro and Wegovy?

CagriSema combines semaglutide, the active medicine in Wegovy, with cagrilintide, which acts on amylin receptors. Mounjaro (tirzepatide) works differently, acting on both GIP and GLP-1 receptors.

A head-to-head trial involving 809 people followed for 84 weeks found average weight loss of 23% with CagriSema and 25.5% with tirzepatide. CagriSema did not meet the trial’s non-inferiority endpoint, meaning the study did not establish that it was no less effective than tirzepatide. This is a result to interpret neutrally: it does not, by itself, determine which medicine is right for a person. [3]

Trial results cannot always be compared directly. Participants, study length and analysis methods can differ. For a UK overview of currently used medicines, read our comparison of Mounjaro and Wegovy and our guide to Wegovy.

Is CagriSema available in the UK?

No. CagriSema is not licensed in the UK and is not available from SwiftDoctor. There is no confirmed UK launch date or NHS availability.

NICE has cagrilintide–semaglutide in its work programme under project GID-TA12443. It is listed as awaiting development, with publication to be confirmed; the topic-prioritisation decision was published on 10 June 2026. This is not a recommendation to use the medicine and does not confirm when, or whether, it will become available. [1]

Our clinicians prescribe licensed medicines only after an individual assessment. Please do not buy CagriSema, cagrilintide or another unapproved medicine online. Products sold outside regulated supply chains may not contain what they claim, and their quality and safety cannot be assured.

What else is coming in the amylin class?

CagriSema is not the only candidate being studied. The results below are from clinical trials, not proof that these medicines are safe, effective or suitable for routine use.

  • Petrelintide, developed by Roche and Zealand Pharma, produced average weight change of −10.7% versus −1.7% with placebo in the phase 2 ZUPREME-1 trial after 42 weeks. Nausea was reported by 19.6% versus 6.2%; vomiting by 3.0% versus 6.2%. Only 1.5% stopped treatment because of gastrointestinal effects. Its more moderate weight-loss result and side-effect profile are one reason researchers are interested in options that may be easier to tolerate. [6]
  • Eloralintide, an investigational medicine from Eli Lilly, produced about 20% average weight change at the 9 mg weekly dose versus −0.4% with placebo over 48 weeks in a phase 2 trial. Vomiting occurred in 11% of people who started directly at 9 mg, compared with 2% of those stepped up from 3 mg. It is a useful illustration of why gradual dose increases can matter. [5]
  • Zenagamtide, previously called amycretin, is a single molecule designed to act on both GLP-1 and amylin receptors. Early studies have reported more than 20% weight loss with injections at 36 weeks. In people with type 2 diabetes, weekly injections were associated with −14.5% weight change and a 1.8% HbA1c reduction; once-daily tablets with −10.1% weight change and a 1.5% HbA1c reduction. These are investigational results. [5]
  • Cagrilintide on its own produced −10.8% weight change versus −3% with placebo at 26 weeks in a phase 2 trial of a 4.5 mg weekly dose. It was better tolerated gastrointestinally than the active comparator used in that trial. [5]

Blank weekly planner beside a navy pen and glass of water

What does this mean for you now?

Nothing in this research changes what you can be prescribed today. UK treatment choices include licensed options such as semaglutide and tirzepatide, as well as newer oral treatments. Each needs clinical review, and the right option depends on your health, treatment goals and preferences. You can see the medicines we currently prescribe on our weight-loss treatment page.

In future, amylin-based medicines might offer an alternative for some people who cannot tolerate GLP-1 side effects, an add-on for people whose weight loss has stalled, or an option for those who do not need a very large reduction. These are possibilities to test, not current prescribing advice.

Tolerability matters. A medicine that is easier to continue may be more useful for some people than one with a higher average result in a trial. Medscape’s coverage of the emerging research notes that around half of people may stop GLP-1 medicines in real-world use, for a range of reasons. That figure is not a prediction for any one patient, but it underlines why individual follow-up and manageable treatment plans matter. [6]

Our clinicians already review dose and tolerability individually rather than assuming that everyone should reach the highest dose. If you are thinking about treatment or a longer-term plan, you can read about weight-loss maintenance or ask a clinician about your options.

When should you speak to a clinician?

Speak to a clinician if you are taking a prescribed weight-loss medicine and have persistent or worsening side effects, are struggling to keep fluids down, or are unsure whether to change or stop your dose. Seek urgent medical help for severe or persistent abdominal pain, repeated vomiting with signs of dehydration, or another severe or rapidly worsening symptom.

If you have bought an unapproved medicine online, do not use it. Contact a pharmacist or clinician for advice about what to do next.

Frequently asked questions

What is CagriSema?

CagriSema is an investigational once-weekly injection combining cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 medicine. In REDEFINE 1 it produced average weight change of −20.4% over 68 weeks, but it is not licensed in the UK. [2, 3]

Is CagriSema available in the UK yet?

No. CagriSema is not licensed or available in the UK, and there is no confirmed UK launch date or NHS availability. SwiftDoctor does not prescribe it.

Is CagriSema better than Mounjaro?

A head-to-head trial reported average weight loss of 23% with CagriSema and 25.5% with tirzepatide (Mounjaro) over 84 weeks; CagriSema did not meet the trial’s non-inferiority endpoint. This does not establish which treatment is best for an individual, and CagriSema is not currently available in the UK. [3]

What are the side effects of CagriSema?

In trials, digestive effects were the most common side effects, especially during dose escalation, and were mostly mild to moderate. Treatment was stopped because of side effects by 6% of participants in REDEFINE 1 and 8% in REDEFINE 2. [3]

When will amylin weight loss injections be available in the UK?

There is no confirmed UK availability date for CagriSema or other amylin-based weight-loss medicines. NICE has the cagrilintide–semaglutide topic in its work programme, but its status does not confirm approval or a launch date. [1]

Sources

  1. NICE. Cagrilintide–semaglutide for managing overweight and obesity, GID-TA12443.
  2. Novo Nordisk. REDEFINE 1 trial synopsis.
  3. Medscape. Significant Weight Loss With CagriSema, but Less Than Hoped.
  4. Walker CS et al. Nature Reviews Endocrinology. Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus.
  5. Medscape. Amylin: A Novel Diabetes and Obesity Therapy.
  6. Medscape. Petrelintide Tolerability Could Improve on GLP-1 Challenges.

This guide is for general information and isn't a substitute for personal medical advice. If you're unsure whether a treatment is right for you, speak to a clinician.

Thinking about weight loss treatment?
Complete an online consultation and a UK-registered clinician will review whether treatment is right for you. You can also book a GP appointment.

This guide is for general information and isn't a substitute for personal medical advice. If you're unsure whether a treatment is right for you, speak to a clinician.

Want to talk it through?

Book a private GP appointment at a time that suits you.

Book a GP appointment

Leave a comment

Please note, comments need to be approved before they are published.